News and Announcements
Benitec Biopharma Annual Update 2015; Lists on the NASDAQ
- Published January 04, 2016 4:01PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Benitec Biopharma (ASX:BLT; NASDAQ:BNTC) is a clinical-stage, biotechnology company developing therapeutics based on its patented gene-silencing technology called ddRNAi.
Its unique therapies target specific genes, genetic disorders and infectious diseases including hepatitis C and B, wet Age-related Macular Degeneration (AMD) and Oculopharyngeal Muscular Dystrophy (OPMD). Benitec’s strategy is to develop its technology in-house, through partnerships with other biotechnology and pharma companies, as well as through out-licensing collaborations.
This year, the company has successfully listed on the NASDAQ, released positive in vitro data for its hepatitis B program and announced encouraging preliminary data from its Phase I/IIa hepatitis C clinical trial, the company’s lead program.
Benitec has a cash position, at 30 September 2015, of approximately AU$33 million. We expect to have significant advances on all of our programs in the next 12 months.
ABOUT BENITEC BIOPHARMA LIMITED
Benitec Biopharma Limited is a publicly listed (ASX:BLT) biotechnology company whose key assets are exclusive irrevocable worldwide rights to a platform technology which has the potential to permanently silence any gene associated with human diseases or conditions. Benitec Biopharma is demonstrating the efficacy and safety of this technology through collaboration with leading organisations globally.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
